Sickle cell anemia and COVID-19: Use of voxelotor to avoid transfusion.

Ershler, William B; Holbrook, Margaret E

Ershler, William B; Holbrook, Margaret E.

Ershler WB; Benign Hematology Division, Inova Schar Cancer Institute, Fairfax, Virginia, USA.
Holbrook ME; Benign Hematology Division, Inova Schar Cancer Institute, Fairfax, Virginia, USA.

Transfusion ; 60(12): 3066-3067, 2020 12.

Article in English | MEDLINE | ID: covidwho-724380

Subject(s)

Anemia, Sickle Cell/complications; Benzaldehydes/therapeutic use; COVID-19/complications; Hematologic Agents/therapeutic use; Pyrazines/therapeutic use; Pyrazoles/therapeutic use; Adult; Anemia, Sickle Cell/blood; Anemia, Sickle Cell/drug therapy; Anemia, Sickle Cell/therapy; COVID-19/diagnosis; COVID-19 Nucleic Acid Testing; Combined Modality Therapy; Erythrocyte Transfusion; Female; Hemoglobins/analysis; Humans; Hypoxia/etiology

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pyrazines / Pyrazoles / Benzaldehydes / COVID-19 / Hematologic Agents / Anemia, Sickle Cell Type of study: Case report / Diagnostic study Topics: Long Covid Limits: Adult / Female / Humans Language: English Journal: Transfusion Year: 2020 Document Type: Article Affiliation country: Trf.16068

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google